Protagonist Therapeutics (PTGX) News Today $60.98 +1.76 (+2.97%) As of 10:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Why Is Protagonist Therapeutics Up Today?Toggle Visibility of Why Is Protagonist Therapeutics Up Today?Protagonist Therapeutics (NASDAQ:PTGX) shares have moved higher as a wave of bullish analyst actions and bullish theses hit the wires. Key developments include: Positive Sentiment: Barclays initiated coverage on PTGX with an “overweight” rating and a $72 price target, signaling strong confidence in the company’s outlook. Protagonist Therapeutics (NASDAQ:PTGX) Now Covered by Barclays Positive Sentiment: Barclays PLC upgraded PTGX to a “strong-buy” rating, reinforcing an aggressive bullish stance. The Fly: PTGX Protagonist Therapeutics Initiated with Bullish View at Barclays Zacks.com Positive Sentiment: HC Wainwright kicked off coverage with a “buy” rating on PTGX, adding another layer of analyst support. Protagonist Therapeutics (NASDAQ:PTGX) Receives "Buy" Rating from HC Wainwright Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and set an $80 price target—implying over 30% potential upside. Benzinga Positive Sentiment: A bull-case theory published on MSN highlights PTGX’s robust pipeline and attractive valuation, making a case for further gains. Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory Positive Sentiment: An in-depth bull case on InsiderMonkey underscores PTGX’s improving P/E metrics and pipeline strengths. Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory Positive Sentiment: Barclays backed biotech with fresh calls on oncology and immunology stocks—PTGX among them—reinforcing sector-wide appeal. Barclays Backs Biotech with Fresh Calls on Oncology and Immunology Stocks Neutral Sentiment: A Benzinga roundup compiles insights from four analyst reviews, providing a balanced overview of PTGX’s valuation and catalyst timeline. Demystifying Protagonist Therapeutics: Insights From 4 Analyst Reviews Posted 15m agoAI Generated. May Contain Errors. PTGX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Protagonist Therapeutics (NASDAQ:PTGX) Now Covered by Barclays3 hours ago | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Receives "Buy" Rating from HC WainwrightSeptember 18 at 4:11 AM | americanbankingnews.comBarclays Initiates Coverage of Protagonist Therapeutics (PTGX) with Overweight RecommendationSeptember 17 at 6:28 PM | msn.comDemystifying Protagonist Therapeutics: Insights From 4 Analyst ReviewsSeptember 17 at 6:28 PM | benzinga.comProtagonist Therapeutics, Inc. (PTGX): A Bull Case TheorySeptember 17 at 6:28 PM | msn.comProtagonist Therapeutics, Inc. (PTGX): A Bull Case Theory September 17 at 12:31 PM | insidermonkey.comBarclays backs biotech with fresh calls on oncology and immunology stocksSeptember 17 at 5:18 AM | investing.comProtagonist Therapeutics initiated with an Overweight at BarclaysSeptember 16 at 12:18 AM | msn.comProtagonist Therapeutics: Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025September 16 at 10:47 AM | finanznachrichten.deQ3 Earnings Estimate for PTGX Issued By Leerink PartnrsSeptember 16 at 2:09 AM | americanbankingnews.comWhat is Leerink Partnrs' Estimate for PTGX Q3 Earnings?September 16 at 2:09 AM | marketbeat.comExploring High Growth Tech Stocks in the US Market September 2025September 15 at 3:08 PM | finance.yahoo.comProtagonist Therapeutics (NASDAQ:PTGX) Upgraded at Leerink PartnrsSeptember 15 at 5:52 AM | marketbeat.comProtagonist Therapeutics, Inc. $PTGX Shares Acquired by Inspire Investing LLCSeptember 15 at 5:17 AM | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Earns Outperform Rating from Analysts at Leerink PartnersSeptember 15 at 2:43 AM | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Upgraded by Leerink Partnrs to Strong-Buy RatingSeptember 15 at 2:48 AM | americanbankingnews.comLeerink Partners Initiates Coverage on Protagonist Therapeutics (NASDAQ:PTGX)September 14, 2025 | marketbeat.comFocus Partners Wealth Boosts Holdings in Protagonist Therapeutics, Inc. $PTGXSeptember 14, 2025 | marketbeat.comEmpowered Funds LLC Takes $4.96 Million Position in Protagonist Therapeutics, Inc. $PTGXSeptember 14, 2025 | marketbeat.comProtagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines AgencySeptember 13, 2025 | finance.yahoo.comFred Alger Management LLC Invests $362,000 in Protagonist Therapeutics, Inc. $PTGXSeptember 13, 2025 | marketbeat.comProtagonist Therapeutics initiated with an Outperform at LeerinkSeptember 12, 2025 | msn.comLeerink Partners Initiates Coverage of Protagonist Therapeutics (PTGX) with Outperform RecommendationSeptember 12, 2025 | msn.comGreat Lakes Advisors LLC Acquires 90,371 Shares of Protagonist Therapeutics, Inc. $PTGXSeptember 12, 2025 | marketbeat.comProtagonist Therapeutics announces icotrokinra application submitted to EMASeptember 11, 2025 | msn.comWoodline Partners LP Purchases 315,372 Shares of Protagonist Therapeutics, Inc. $PTGXSeptember 11, 2025 | marketbeat.com39,969 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Axiom Investors LLC DESeptember 11, 2025 | marketbeat.com20,765 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Coppell Advisory Solutions LLCSeptember 11, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (PTGX) Presents At H.C. Wainwright 27th Annual Global Investment Conference TranscriptSeptember 11, 2025 | seekingalpha.comProtagonist Therapeutics (NASDAQ:PTGX) Trading Down 8.7% - What's Next?September 10, 2025 | marketbeat.comScientech Research LLC Grows Position in Protagonist Therapeutics, Inc. $PTGXSeptember 10, 2025 | marketbeat.comState of Wyoming Reduces Position in Protagonist Therapeutics, Inc. $PTGXSeptember 10, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Invests $16.61 Million in Protagonist Therapeutics, Inc. $PTGXSeptember 8, 2025 | marketbeat.comNew Vernon Capital Holdings II LLC Has $16.83 Million Stock Holdings in Protagonist Therapeutics, Inc. $PTGXSeptember 7, 2025 | marketbeat.comEFG Asset Management North America Corp. Purchases Shares of 71,134 Protagonist Therapeutics, Inc. $PTGXSeptember 6, 2025 | marketbeat.comCheckpoint Capital L.P. Takes Position in Protagonist Therapeutics, Inc. $PTGXSeptember 6, 2025 | marketbeat.comProtagonist Therapeutics, Inc. $PTGX is BVF Inc. IL's 6th Largest PositionSeptember 5, 2025 | marketbeat.com683 Capital Management LLC Acquires 90,000 Shares of Protagonist Therapeutics, Inc. $PTGXSeptember 4, 2025 | marketbeat.comADAR1 Capital Management LLC Has $45.44 Million Holdings in Protagonist Therapeutics, Inc. $PTGXSeptember 4, 2025 | marketbeat.comHighTower Advisors LLC Makes New Investment in Protagonist Therapeutics, Inc. $PTGXSeptember 4, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (PTGX) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 3, 2025 | seekingalpha.com149,908 Shares in Protagonist Therapeutics, Inc. $PTGX Acquired by Panagora Asset Management Inc.September 3, 2025 | marketbeat.comMagnetar Financial LLC Invests $539,000 in Protagonist Therapeutics, Inc. $PTGXSeptember 3, 2025 | marketbeat.comTrexquant Investment LP Buys 11,195 Shares of Protagonist Therapeutics, Inc. $PTGXSeptember 3, 2025 | marketbeat.comLandscape Capital Management L.L.C. Purchases Shares of 7,758 Protagonist Therapeutics, Inc. $PTGXSeptember 3, 2025 | marketbeat.comDriehaus Capital Management LLC Decreases Stock Holdings in Protagonist Therapeutics, Inc. $PTGXSeptember 2, 2025 | marketbeat.comRafferty Asset Management LLC Cuts Position in Protagonist Therapeutics, Inc. $PTGXSeptember 2, 2025 | marketbeat.comNorthern Trust Corp Buys 10,927 Shares of Protagonist Therapeutics, Inc. $PTGXSeptember 1, 2025 | marketbeat.comProtagonist Therapeutics, Inc. $PTGX Shares Sold by Raymond James Financial Inc.August 31, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Director Sells $237,000.00 in StockAugust 30, 2025 | insidertrades.com Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PTGX Media Mentions By Week PTGX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTGX News Sentiment▼0.760.63▲Average Medical News Sentiment PTGX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTGX Articles This Week▼327▲PTGX Articles Average Week Get the Latest News and Ratings for PTGX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Protagonist Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Summit Therapeutics News Dr. Reddy's Laboratories News Ascendis Pharma A/S News Viatris News Qiagen News BridgeBio Pharma News Roivant Sciences News Verona Pharma PLC American Depositary Share News Elanco Animal Health News Moderna News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTGX) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTen Bucks, Five Minutes... Could Send You Up to $8K QUARTERLYDOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTGX Stock Alerts